Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report

Abstract Background Hepatocellular carcinoma (HCC) with major portal vein tumor thrombus (Vp4 PVTT) is an extremely advanced tumor with limited treatment options. Systemic chemotherapy is the only recommended treatment option, and atezolizumab plus bevacizumab has recently emerged as a first-line tr...

詳細記述

書誌詳細

主要な著者:	Shohei Komatsu, Yoshimi Fujishima, Masahiro Kido, Kaori Kuramitsu, Tadahiro Goto, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2021-12-01
シリーズ:	BMC Gastroenterology
主題:	Hepatocellular carcinoma Atezolizumab plus bevacizumab Portal vein tumor thrombus Case report
オンライン･アクセス:	https://doi.org/10.1186/s12876-021-02053-4
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!